Anton B Iliuk1, W Andy Tao. 1. Department of Biochemistry, Purdue University, West Lafayette, IN 47907, United States.
Abstract
BACKGROUND: For many diseases such as cancer where phosphorylation-dependent signaling is the foundation of disease onset and progression, single-gene testing and genomic profiling alone are not sufficient in providing most critical information. The reason for this is that in these activated pathways the signaling changes and drug resistance are often not directly correlated with changes in protein expression levels. In order to obtain the essential information needed to evaluate pathway activation or the effects of certain drugs and therapies on the molecular level, the analysis of changes in protein phosphorylation is critical. METHODS: Existing approaches do not differentiate clinical disease subtypes on the protein and signaling pathway level, and therefore hamper the predictive management of the disease and the selection of therapeutic targets. CONCLUSIONS: The mini-review examines the impact of emerging systems biology tools and the possibility of applying phosphoproteomics to clinical research.
BACKGROUND: For many diseases such as cancer where phosphorylation-dependent signaling is the foundation of disease onset and progression, single-gene testing and genomic profiling alone are not sufficient in providing most critical information. The reason for this is that in these activated pathways the signaling changes and drug resistance are often not directly correlated with changes in protein expression levels. In order to obtain the essential information needed to evaluate pathway activation or the effects of certain drugs and therapies on the molecular level, the analysis of changes in protein phosphorylation is critical. METHODS: Existing approaches do not differentiate clinical disease subtypes on the protein and signaling pathway level, and therefore hamper the predictive management of the disease and the selection of therapeutic targets. CONCLUSIONS: The mini-review examines the impact of emerging systems biology tools and the possibility of applying phosphoproteomics to clinical research.
Authors: Liang Xue; Wen-Horng Wang; Anton Iliuk; Lianghai Hu; Jacob A Galan; Shuai Yu; Michael Hans; Robert L Geahlen; W Andy Tao Journal: Proc Natl Acad Sci U S A Date: 2012-03-26 Impact factor: 11.205
Authors: Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau Journal: Mol Cancer Ther Date: 2006-10 Impact factor: 6.261
Authors: Jannik N Andersen; Sriram Sathyanarayanan; Alessandra Di Bacco; An Chi; Theresa Zhang; Albert H Chen; Brian Dolinski; Manfred Kraus; Brian Roberts; William Arthur; Rich A Klinghoffer; Diana Gargano; Lixia Li; Igor Feldman; Bethany Lynch; John Rush; Ronald C Hendrickson; Peter Blume-Jensen; Cloud P Paweletz Journal: Sci Transl Med Date: 2010-08-04 Impact factor: 17.956
Authors: Maria P Alcolea; Pedro Casado; Juan-Carlos Rodríguez-Prados; Bart Vanhaesebroeck; Pedro R Cutillas Journal: Mol Cell Proteomics Date: 2012-04-29 Impact factor: 5.911
Authors: Ulrik B Nielsen; Mike H Cardone; Anthony J Sinskey; Gavin MacBeath; Peter K Sorger Journal: Proc Natl Acad Sci U S A Date: 2003-07-22 Impact factor: 11.205
Authors: Thomas O'Hare; Denise K Walters; Eric P Stoffregen; Taiping Jia; Paul W Manley; Jürgen Mestan; Sandra W Cowan-Jacob; Francis Y Lee; Michael C Heinrich; Michael W N Deininger; Brian J Druker Journal: Cancer Res Date: 2005-06-01 Impact factor: 12.701
Authors: C Bart Rountree; Colleen A Van Kirk; Hanning You; Wei Ding; Hien Dang; Heather D VanGuilder; Willard M Freeman Journal: Proteome Sci Date: 2010-11-22 Impact factor: 2.480
Authors: Yury O Nunez Lopez; Anton Iliuk; Alejandra M Petrilli; Carley Glass; Anna Casu; Richard E Pratley Journal: Int J Mol Sci Date: 2022-05-21 Impact factor: 6.208
Authors: Anna M Zawadzka; Birgit Schilling; Michael P Cusack; Alexandria K Sahu; Penelope Drake; Susan J Fisher; Christopher C Benz; Bradford W Gibson Journal: Mol Cell Proteomics Date: 2014-02-06 Impact factor: 5.911